Intas Pharmaceuticals
Corporate brand
UnclaimedIndian multinational pharmaceutical company focused on generic medicines, biosimilars, contract research, and manufacturing.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Intas Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat. Founded by pharmacist Hasmukh Chudgar in 1977 and incorporated in 1985, the company develops, manufactures, and markets generic medicines, biosimilars, specialty pharmaceuticals, and related healthcare products. Its activities also include contract clinical research and contract manufacturing. Intas sells through India-based operations and international subsidiaries, with reported commercial reach in more than 100 countries. The company has built a particularly strong presence in regulated international markets through Accord Healthcare, its London-headquartered subsidiary. Accord focuses on large-scale generic pharmaceuticals in Europe and North America and operates research, regulatory, commercial, and manufacturing activities across several countries. Intas expanded its international manufacturing footprint through facilities in India, the United Kingdom, Mexico, and Greece, although the number and configuration of operating sites has changed over time. Publicly described manufacturing networks have included more than a dozen Indian facilities alongside European and Mexican locations. Intas also operates a biologics business that originated as Intas Biopharmaceuticals. Established as an independent biotechnology division in 2000 under Urmish Chudgar, a hematologist, the unit was later merged into Intas Pharmaceuticals during 2012–13. It develops and manufactures biosimilars based on recombinant DNA technology and monoclonal antibodies. Its regulatory history includes European Good Manufacturing Practice certification for a biosimilar filgrastim program, followed by the launch of a filgrastim product in Europe in 2015. The group expanded through acquisitions and asset purchases. In 2016, it acquired Teva Pharmaceutical Industries' United Kingdom and Ireland assets for approximately US$764 million. In 2017, Accord Healthcare acquired Actavis UK and Actavis Ireland from Teva for an enterprise value reported at approximately £603 million, including a portfolio of generic medicines and a manufacturing facility in Barnstaple. Accord also acquired and later reopened Sanofi's Fawdon plant in the United Kingdom for generic effervescent medicines. Intas remains privately controlled rather than publicly listed. Reported ownership information has placed the Chudgar family in control, with minority interests held by investment firms including Temasek Holdings and ChrysCapital. The company has attracted regulatory and quality scrutiny, including a 2020 Indian pricing-compliance notice, a 2022 United States Food and Drug Administration inspection identifying alleged data-integrity failures at its Sanand facility, and subsequent concerns about the interchangeability performance of an Intas-manufactured generic tacrolimus product. These matters are significant to the company's current profile because pharmaceutical quality, data integrity, and regulatory compliance directly affect product approvals and international market access.
History
Intas Pharmaceuticals traces its origins to 1977, when pharmacist Hasmukh Chudgar established the business in India. The company was formally incorporated in 1985. Its early development was centered on pharmaceutical manufacturing and therapeutic medicines for the Indian market, but it subsequently expanded toward international generic-drug markets, contract research, contract manufacturing, and biologic products. A major strategic development was the creation of Intas Biopharmaceuticals in 2000 as an independent biotechnology division under Urmish Chudgar, a hematologist. The division focused on biosimilars and biologic manufacturing using recombinant DNA technology and monoclonal antibodies. It pursued international regulatory recognition, including a European GMP audit in 2006 connected with a filgrastim clinical-trial program. The facility was certified as EU GMP-compliant in 2007, a milestone described as a first of its kind for an Indian company in this context. The biologics division was merged into the parent company during 2012–13. Intas strengthened its position in Europe and North America through Accord Healthcare, a London-based wholly owned subsidiary. Accord became a major vehicle for generic-drug commercialization and maintained an American research and development presence in Research Triangle Park, North Carolina. By 2018, Accord was reported to hold approvals for 89 abbreviated new drug applications and to market 255 dosage presentations. The group also used acquisitions to increase its manufacturing and product coverage. In 2016, Intas purchased Teva's United Kingdom and Ireland assets for a reported US$764 million. In 2017, Accord Healthcare acquired Actavis UK and Actavis Ireland from Teva for a reported enterprise value of £603 million. The transaction included generic medicines and the Barnstaple manufacturing facility. Accord's United Kingdom network was further expanded through the reopening of Sanofi's Fawdon plant, acquired after Sanofi closed it, for the manufacture of generic effervescent medicines. Manufacturing expansion continued in India and overseas. Public descriptions have identified facilities in India, the United Kingdom, Mexico, and Greece, with facility counts varying by reporting date and corporate organization. A new site in the PHARMEZ pharmaceutical park at Bavla near Ahmedabad was described as having capacity for more than one billion solid doses and five million injectables. By March 2021, the company was reported to operate 19 manufacturing facilities globally, including 13 in India, five in the United Kingdom, and one in Mexico. The company has remained privately controlled. Reported ownership changes included ChrysCapital's acquisition of a 16.14% stake in 2013, the sale of 10.13% of that interest to Temasek Holdings in 2015, and a further 3.01% dilution to Capital International in 2017. By May 2020, ChrysCapital was reported to have repurchased Capital International's interest. The resulting reported ownership structure placed approximately 83.85% with the Chudgar family, 10.13% with Temasek Holdings, and 6.02% with ChrysCapital. Intas's international expansion has also brought regulatory and quality challenges. In 2020, the company received an Indian price-control show-cause notice concerning an anti-diabetic medicine. In December 2022, an FDA inspection of its Sanand site reported serious alleged data-integrity violations, including manipulated laboratory results and destruction of quality records. In 2023, independent testing of generic tacrolimus associated with Intas raised further questions about therapeutic equivalence. These developments have added compliance and manufacturing-quality risk to the company's otherwise expansion-oriented international strategy.
- 2022
Sanand facility FDA inspection
[1]A US FDA inspection reported alleged laboratory-data manipulation and destruction of quality records at the Sanand site.
- 2021
Global manufacturing network reported
[1]As of March 2021, Intas was reported to operate 19 manufacturing facilities globally.
- 2018
Accord expands generic portfolio
[1]Accord was reported to hold 89 abbreviated new drug application approvals and market 255 dosage presentations.
- 2017
Actavis UK and Ireland acquired by Accord
[1]Accord Healthcare acquired Actavis UK and Actavis Ireland from Teva, including the Barnstaple plant.
- 2016
Teva UK and Ireland assets acquired
[1]Intas acquired Teva's United Kingdom and Ireland assets for a reported US$764 million.
- 2015
European filgrastim launch
[1]Intas launched its first biosimilar filgrastim product in Europe.
- 2013
ChrysCapital takes a minority stake
[1]ChrysCapital acquired a reported 16.14% interest in Intas.
- 2007
EU GMP certification milestone
[1]The biologics operation obtained EU GMP certification following an audit connected with its European filgrastim development program.
- 2000
Biopharmaceutical division established
[1]Intas Biopharmaceuticals was established as an independent biotechnology division focused on biosimilars and biologic manufacturing.
- 1985
Company incorporated
[1]Intas Pharmaceuticals was formally incorporated.
Products and positioning
A privately controlled Indian pharmaceutical group positioned around affordable generic medicines, international regulated-market access, biosimilars, and vertically integrated research and manufacturing. Through Accord Healthcare, it has emphasized broad generic portfolios and commercialization in Europe and North America.
Biosimilars · 2015
Filgrastim biosimilars
Intas's biologics division developed recombinant filgrastim products for international markets. Filgrastim is used in settings involving neutropenia and immune-system impairment. The program helped establish the company's European regulatory and manufacturing credentials, with the first Intas biosimilar filgrastim launch in Europe reported in 2015.
Generics
Generic prescription medicines
Generic medicines are the core of Intas's business. The company manufactures oral solid doses, injectables, and other dosage forms across a broad therapeutic portfolio, selling through Indian operations and international subsidiaries. Accord Healthcare provides a major route to European and North American markets.
Immunosuppressants
Tacrolimus generics
Intas-associated generic tacrolimus products have been marketed as substitutes for reference tacrolimus medicines. Tacrolimus is a narrow-therapeutic-index immunosuppressant. Independent testing reported in 2023 raised concerns about whether one Intas product performed equivalently to the branded reference product.
Generics · 2018
Generic effervescent medicines
Through Accord's United Kingdom manufacturing network, Intas produces generic effervescent medicines. The Fawdon facility was reopened for this purpose after being acquired following Sanofi's closure of the site.
Pharmaceutical services
Contract research and manufacturing
Alongside branded and generic product development, Intas undertakes contract clinical research and manufacturing activities. These capabilities support pharmaceutical partners with development, regulatory, and production requirements.
Controversies
2023
Tacrolimus equivalence concerns
Valisure testing conducted for the American military reportedly found that an Intas-produced generic tacrolimus did not perform as an equivalent substitute for the reference product. The report also referenced earlier concerns involving an Accord tacrolimus product.
2022
Alleged laboratory data falsification at Sanand
A US FDA inspection reported alleged intentional manipulation of laboratory results and destruction of critical quality-control records at Intas's Sanand manufacturing facility.
2020
Indian price-control compliance notice
The National Pharmaceutical Pricing Authority issued a show-cause notice to Intas over an allegation that an anti-diabetic medicine had been sold without mandatory price approval.
Brand decisions
2018
Reopening of the Fawdon manufacturing plantStrategyBackground
Sanofi had closed its Fawdon facility in the United Kingdom, which had previously produced effervescent medicines.
Action taken
Accord reopened the Fawdon site to manufacture generic effervescent medicines.
Aftermath
The site became part of Accord's expanding United Kingdom manufacturing network.
2017
Accord acquisition of Actavis UK and IrelandM&ABackground
Accord Healthcare pursued additional European generic medicines and manufacturing capacity.
Action taken
Accord acquired Actavis UK and Actavis Ireland from Teva, including a generic portfolio and the Barnstaple plant.
Aftermath
Accord increased its United Kingdom and Ireland commercial and production presence.
Reported enterprise value. £603 million (2017)
2016
Acquisition of Teva UK and Ireland assetsM&ABackground
Intas sought to expand its presence in regulated European generic-drug markets.
Action taken
Intas acquired Teva Pharmaceutical Industries' United Kingdom and Ireland assets.
Aftermath
The transaction expanded Intas's European portfolio and operating footprint.
Reported acquisition price. US$764 million (2016)
2012
Biologics division merged into IntasStrategyBackground
Intas had developed a separate biotechnology operation focused on biosimilars and recombinant biologics.
Action taken
The Intas Biopharmaceuticals division was merged into Intas Pharmaceuticals during 2012–13.
Aftermath
The biologics capabilities became part of the parent company's integrated pharmaceutical platform.
Recent events
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/intas-pharmaceuticals · Editorial policy · How profiles are compiled